TY - JOUR
T1 - Ways to improve breast cancer patients' management and clinical outcome
T2 - The 2020 Assisi Think Tank Meeting
AU - Aristei, Cynthia
AU - Bölükbaşı, Yasemin
AU - Kaidar-Person, Orit
AU - Pfeffer, Raphael
AU - Arenas, Meritxell
AU - Boersma, Liesbeth J.
AU - Ciabattoni, Antonella
AU - Coles, Charlotte E.
AU - Franco, Pierfrancesco
AU - Krengli, Marco
AU - Leonardi, Maria Cristina
AU - Marazzi, Fabio
AU - Masiello, Valeria
AU - Meattini, Icro
AU - Montero, Angel
AU - Offersen, Birgitte
AU - Trigo, Maria Lurdes
AU - Bourgier, Céline
AU - Genovesi, Domenico
AU - Kouloulias, Vassilis
AU - Morganti, Alessio G.
AU - Meduri, Bruno
AU - Pasinetti, Nadia
AU - Pedretti, Sara
AU - Perrucci, Elisabetta
AU - Rivera, Sofia
AU - Tombolini, Vincenzo
AU - Vidali, Cristiana
AU - Valentini, Vincenzo
AU - Poortmans, Philip
N1 - Publisher Copyright:
© 2022
PY - 2022/9
Y1 - 2022/9
N2 - We report on the third Assisi Think Tank Meeting (ATTM) on breast cancer, a brainstorming project which involved European radiation and clinical oncologists who were dedicated to breast cancer research and treatment. Held on February 2020, the ATTM aimed at identifying key clinical questions in current clinical practice and “grey” areas requiring research to improve management and outcomes. Before the meeting, three key topics were selected: 1) managing patients with frailty due to either age and/or multi-morbidity; 2) stereotactic radiation therapy and systemic therapy in the management of oligometastatic disease; 3) contralateral breast tumour prevention in BCRA-mutated patients. Clinical practice in these areas was investigated by means of an online questionnaire. In the lapse period between the survey and the meeting, the working groups reviewed data, on-going studies and the clinical challenges which were then discussed in-depth and subjected to intense brainstorming during the meeting; research protocols were also proposed. Methodology, outcome of discussions, conclusions and study proposals are summarized in the present paper. In conclusion, this report presents an in-depth analysis of the state of the art, grey areas and controversies in breast cancer radiation therapy and discusses how to confront them in the absence of evidence-based data to guide clinical decision-making.
AB - We report on the third Assisi Think Tank Meeting (ATTM) on breast cancer, a brainstorming project which involved European radiation and clinical oncologists who were dedicated to breast cancer research and treatment. Held on February 2020, the ATTM aimed at identifying key clinical questions in current clinical practice and “grey” areas requiring research to improve management and outcomes. Before the meeting, three key topics were selected: 1) managing patients with frailty due to either age and/or multi-morbidity; 2) stereotactic radiation therapy and systemic therapy in the management of oligometastatic disease; 3) contralateral breast tumour prevention in BCRA-mutated patients. Clinical practice in these areas was investigated by means of an online questionnaire. In the lapse period between the survey and the meeting, the working groups reviewed data, on-going studies and the clinical challenges which were then discussed in-depth and subjected to intense brainstorming during the meeting; research protocols were also proposed. Methodology, outcome of discussions, conclusions and study proposals are summarized in the present paper. In conclusion, this report presents an in-depth analysis of the state of the art, grey areas and controversies in breast cancer radiation therapy and discusses how to confront them in the absence of evidence-based data to guide clinical decision-making.
KW - BCRA-mutated patients
KW - Breast cancer
KW - Contralateral breast cancer prevention
KW - De-escalating therapy
KW - Oligometastatic disease
KW - Radiation therapy
KW - Stereotactic radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85135910637&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2022.103774
DO - 10.1016/j.critrevonc.2022.103774
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 35917884
AN - SCOPUS:85135910637
SN - 1040-8428
VL - 177
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103774
ER -